Preclinical study shows promise of systemic targeted therapy in a rare form of cancer
byVall d'Hebron Institute of OncologyTreatment with BRAF inhibitors reduces tumor cell proliferation in subcutaneous BRAFV600EPMP-PDX tumors without impacting in apoptosis. a–d) Mice b
Updated on: August 03,2024
0

Preclinical study shows promise of systemic targeted therapy in a rare form of cancer
byVall d'Hebron Institute of OncologyTreatment with BRAF inhibitors reduces tumor cell proliferation in subcutaneous BRAFV600EPMP-PDX tumors without impacting in apoptosis. a–d) Mice b
Updated on:August 03,2024
0
